(Q43638607)

25 November 2017

title

Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients (English)

1 reference

25 November 2017

1 reference

1 reference

Penson MG

1

1 reference

25 November 2017

Fricker FJ

2

1 reference

25 November 2017

Thompson JR

3

1 reference

25 November 2017

Harker K

4

1 reference

25 November 2017

Williams BJ

5

1 reference

25 November 2017

Kahler DA

6

1 reference

25 November 2017

Schowengerdt KO

7

1 reference

25 November 2017

publication date

1 June 2001

1 reference

The Journal of Heart and Lung Transplantation

25 November 2017

published in

1 reference

25 November 2017

volume

20

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

611-618

1 reference

Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Hypercholesterolemia after cardiac transplantation in children

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Frequency of hypercholesterolemia after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Lipoprotein(a) and apolipoprotein changes after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Increased lipid peroxidation in cyclosporin-treated heart transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Effects of pravastatin on chronic rejection of rat cardiac allografts.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

Statins after cardiac transplantation: which statin, what dose, and how low should we go?

1 reference

https://api.crossref.org/works/10.1016%2FS1053-2498%2801%2900251-0

7 January 2021

10.1016/S1053-2498(01)00251-0

Identifiers

DOI

1 reference

25 November 2017

1 reference